News & Updates

The use of the oral GnRH antagonist linzagolix in patients with heavy menstrual bleeding (HMB) due to uterine fibroids induced multiple benefits including improved haemoglobin (Hb) levels, health-related quality of life (HRQoL), and mood, analysis of the PRIMROSE 1 and 2 trials showed.

In pregnant women, serum thyroglobulin (Tg) levels correlate well with urinary iodine concentration (UIC) and iodine-to-creatinine ratio (ICR), and may be a good marker for iodine status, a recent study has found.

Treatment with fezolinetant significantly reduced the frequency and severity of vasomotor symptoms (VMS), particularly hot flashes, in women during their menopausal phase, according to the SKYLIGHT 1* trial presented at ACOG 2022.

Despite policy advancement and nutritional monitoring, salt iodination seems to be an insufficient measure to provide the adequate level of iodine to pregnant women, reports a recent meta-analysis.

Once-daily (QD) administration of low-dose elagolix 150 mg led to significantly reduced heavy menstrual bleeding (HMB) in premenopausal women with uterine fibroids, according to a study presented at ACOG 2022.

A group of Australia-based researchers has developed a novel device that makes intracytoplasmic sperm injection (ICSI) a less technically demanding procedure, reducing dependence on the experience level of embryologists and, in turn, dramatically improving fertilization success.